Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mastitis

Last updated: April 9, 2025
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Soft Tissue Infections

Treatment

Any treatments regimen

Clinical Study ID

NCT06667609
SYSKY-2024-699-01
  • Ages 18-65
  • Female

Study Summary

The purpose of this study is to evaluate the validity and reliability of the Mastitis-score (M-score) and the Breast Inflammatory Symptom Severity Index (BISSI) as measures for assessing symptom severity in non-lactational granulomatous lobular/periductal mastitis (NL-GLM/PDM). This research aims to provide a valid and reliable tool for evaluating both symptom severity and treatment efficacy in NL-GLM/PDM.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Female, age between 18 and 65 years;

  2. Clinically considered as Non-Lactational mastitis;

  3. Clinically and Pathologically confirmed NL-GLM/PDM;

  4. Patients planning to receive treatment or observation alone;

  5. Signed the informed consent form

Exclusion

Exclusion Criteria:

  1. Patients with confirmed or suspected malignant breast tumors

  2. Patients with bilateral mastitis (including those with bilateral Non-LactationalMastitis occurring simultaneously or successively)

  3. Pregnant.

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Any treatments regimen
Phase:
Study Start date:
August 28, 2024
Estimated Completion Date:
June 30, 2027

Study Description

Non-lactational granulomatous lobular/periductal mastitis (NL-GLM/PDM) are inflammatory breast diseases with unclear etiology, usually manifested as palpable breast mass, accompanied by breast pain and abscesses, erythema or fistula formation. There is no well-recognized assessment tool for evaluating the symptom severity and treatment efficacy of NL-GLM/PDM. In our previous studies with NL-GLM, we used the Mastitis-score (M-score) as a physician-directed measure of the symptom severity. However, there were no patient-reported outcome measure for NL-GLM/PDM. The Breast Inflammatory Symptom Severity Index(BISSI) was reported as a valid patient-reported outcome measure for lactational mastitis. Its clinical validity as a measure of Symptom Severity for NL-GLM/PDM are still unclear.

In this multicenter, prospective cohort study, we will validate the validity and reliability of the M-score, a physician-directed measure, and the Breast Inflammatory Symptom Severity Index (BISSI), a patient-reported outcome (PRO) measure, for assessing symptom severity in patients with non-lactational granulomatous lobular/periductal mastitis (NL-GLM/PDM). Establishing the validity of these two approaches will facilitate the objective measurement of treatment efficacy for NL-GLM/PDM in the future.

Connect with a study center

  • Chaozhou Maternal and Child Health Hospital

    Chaozhou, Guangdong 521000
    China

    Active - Recruiting

  • Sun Yat-sen memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong 510120
    China

    Active - Recruiting

  • Jiangmen Maternity and Child Health Care Hospital

    Jiangmen, Guangdong 529051
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.